SIREN : 845007996
MG-PHARMA is a French company founded 7 years ago, specialized in the sector Fonds de placement et entités financières similaires. Based in JŒUF (54240), this company of category PME shows in 2023 a net income negative of -27 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2023 | 2022 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | N/C | N/C | N/C | N/C |
| Net income | -27 171 € | 358 745 € | -34 710 € | -11 550 € |
| EBITDA | -2 187 € | -3 110 € | -2 720 € | -3 259 € |
| Net margin | N/C | N/C | N/C | N/C |
In 2023, MG-PHARMA records a net loss of 27 k€. This deficit will reduce equity on the balance sheet.
-2 187 €
-2 187 €
-27 171 €
The debt ratio (= Financial debt / Equity x 100) stands at 29%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 77%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
29.213%
77.214%
-50.1
In 2023, the debt ratio of MG-PHARMA (29.21) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2023, the financial autonomy of MG-PHARMA (77.2%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2023, the repayment capacity of MG-PHARMA (-50.10) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 2271.23. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
2271.229
0.0
In 2023, the liquidity ratio of MG-PHARMA (2271.23) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
In 2023, the interest coverage of MG-PHARMA (0.0x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 146 days. Excellent situation: suppliers finance 146 days of the operating cycle (retail model).
0 €
0 j
146 j
0 j
Compare MG-PHARMA with other companies in the same sector:
Voir toutes les statistiques du secteur Fonds de placement et entités financières similaires
The revenue of MG-PHARMA is not publicly disclosed (confidential accounts filed with INPI).
MG-PHARMA recorded a net loss in 2023.
The headquarters of MG-PHARMA is located in JŒUF (54240), in the department Meurthe-et-Moselle.
The tax return of MG-PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
MG-PHARMA operates in the sector Fonds de placement et entités financières similaires (NAF code 64.30Z). See the 'Sector positioning' section above to compare the company with its competitors.